Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Conditions: Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma

Interventions: Radiation: Comprehensive Ablative Bridging Irradiation (CABI); Biological: Chimeric Antigen Receptor T-Cell Therapy

Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Kite, A Gilead Company

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 30, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments